Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$2230.00
-62.00 (-2.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $10.2B · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$98.3B
P/E
11.6x
↓EV/EBITDA
5.6x
↓ROE
11.1%
↑Gross Margin
73.3%
↑Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.6%
FCF CAGR
+10.6%
FCF margin
11.7%
FCF / Net income
1.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $87.31B · net income $9.94B · FCF $10.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $87.31B | $87.31B | $75.73B | $68.38B | $59.53B |
| Net Income | $9.94B | $9.94B | $7.73B | $6.20B | $3.96B |
| EBITDA | $20.63B | $20.63B | $17.52B | $13.76B | $11.44B |
| EPS | 225.42 | 225.42 | 175.39 | 140.26 | 87.76 |
| Gross Margin | 73.3% | 73.3% | 73.3% | 72.4% | 70.8% |
| Operating Margin | 14.0% | 14.0% | 12.7% | 13.2% | 10.7% |
| Net Margin | 11.4% | 11.4% | 10.2% | 9.1% | 6.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.58 | 0.76 | 0.95 |
| Current Ratio | 1.48 | 1.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $10.19B | $10.19B | $8.28B | $10.50B | $7.53B |
| Returns | |||||
| ROE | 11.1% | 11.1% | 9.7% | 9.5% | 7.2% |
| Valuation | |||||
| P/E | 11.63 | 11.63 | 11.80 | 16.04 | 22.00 |
| EV/EBITDA | 5.62 | 5.62 | 6.68 | 9.64 | 11.04 |
| P/B | 1.10 | 1.10 | 1.15 | 1.52 | 1.56 |
| Growth & Yield | |||||
| Revenue Growth | 15.3% | 15.3% | 10.7% | 14.9% | — |
| EPS Growth | 28.5% | 28.5% | 25.0% | 59.8% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-4.3%
EPS terminal req.
$197.88
Spread vs growth
32.8%
5Y implied EPS CAGR
1.2%
EPS terminal req.
$239.43
Spread vs growth
27.3%
10Y implied EPS CAGR
5.5%
EPS terminal req.
$385.60
Spread vs growth
23.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.2%
Start / end P/E
12.1x → 9.9x
EPS bridge
175.39 → 225.42
Residual
-5.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.